

27. The method according to Claim 26, wherein said condition is characterized by the occurrence of sprouting.

28. The method according to Claim 26, wherein said condition is characterized by the occurrence of seizures.

29. The method according to Claim 26, wherein said condition is epilepsy.

30. The method according to Claim 29, wherein said method results in a decrease in seizure proneness.

31. The method according to Claim 26, wherein said host is a mammalian host.

32. A method of treating a host suffering from a condition resulting from excessive activity of glutamate receptors, said method comprising:  
administering to said host an amount of a serine protease inhibitor effective to treat said host for said condition.

33. The method according to Claim 32, wherein said excessive activity results from hypoxia, head trauma or stroke.

34. The method according to Claim 32, wherein said host is a mammalian host.

35. A method of treating a host suffering from a condition resulting from exogenous tPA activity, said method comprising:  
administering to said host an amount of a serine protease inhibitor effective to treat said host for said condition.

36. The method according to Claim 35, wherein said serine protease inhibitor is administered to said host after administration of exogenous tPA.

37. The method according to Claim 35, wherein said host is a mammalian host.

38. A method of preventing the onset of a condition characterized by increased synaptic responsiveness in a host, which method comprises:  
administering to said host an amount of a serine protease inhibitor effective to prevent onset of said condition.

39. The method according to Claim 38, wherein said condition is characterized by the occurrence of sprouting.

40. The method according to Claim 38, wherein said condition is characterized by the occurrence of seizures.

41. The method according to Claim 38, wherein said condition is epilepsy.

42. The method according to Claim 38, wherein said host is a mammalian host. --

---

**REMARKS UNDER 37 CFR § 1.111**

**Formal Matters**

Claims 26 to 42 are pending after entry of the amendments set forth herein.

**Amendments**

The Applicants have canceled originally filed Claims 1 to 25 and replaced them with newly presented claims 26 to 42. Claims 26 to 31 are directed to treating a host suffering of a condition associated with increases in synaptic responsiveness and/or increases in synaptic activity, such as epilepsy and related disorders, by administering an effective amount of a serine